This article is more than 5 years old. Information may no longer be current.
Alcon reports $1.3 billion in global third quarter sales
Click Here to Manage Email Alerts
HUNENBERG, Switzerland — Alcon recorded $1.3 billion in global sales for the third quarter of this year, which represents an 11% increase over the third quarter of 2006, the company announced in a press release.
Compared with the third quarter 2006, net earnings for the third quarter 2007 increased 78.9% to total $415.3 million, or $1.38 per diluted share. These earnings include charges related to a workforce reduction in Alcon's refractive laser business, which was associated with its planned acquisition and integration of WaveLight AG.
Excluding these charges, adjusted net earnings for the third quarter increased 29.2% to $418.7 million, or 31.1% to $1.39 per diluted share, compared with the third quarter of 2006, according to the release.
By product category, pharmaceutical sales increased 10.2% to $547.3 million. Specifically, glaucoma product sales increased 19% because of growth in sales of Travatan products and Azopt ophthalmic suspension. Specifically, Travatan products sales increased 30.6%, the release said.
Surgical sales increased 10.8% to $585.9 million. IOL sales increased 12.3% to $215.4 million, with sales of premium IOLs increasing 35.1%. Cataract and vitreoretinal product sales increased 11.5%.
Alcon's refractive revenue decreased 30.3% because of a decrease in per procedure technology fees in the United States.
Consumer eye care sales increased 13.5% to $202.5 million, according to the release.